Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Thrombosis Canada. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Thrombosis Canada or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The COBRA Study: Shifting Paradigms in Acute VTE Treatment

4:34
 
Share
 

Manage episode 491261933 series 3495680
Content provided by Thrombosis Canada. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Thrombosis Canada or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

In this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.

Support the show

https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

  continue reading

42 episodes

Artwork
iconShare
 
Manage episode 491261933 series 3495680
Content provided by Thrombosis Canada. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Thrombosis Canada or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

In this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.

Support the show

https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

  continue reading

42 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play